<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-22T12:23:26Z</responseDate><request verb="GetRecord" identifier="oai:dora.dmu.ac.uk:2086/10751" metadataPrefix="dim">https://dora.dmu.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:dora.dmu.ac.uk:2086/10751</identifier><datestamp>2023-09-20T19:25:46Z</datestamp><setSpec>com_2086_2388</setSpec><setSpec>col_2086_2389</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author" authority="b197f481-9522-4d7d-8816-6a89e1a0afdd" confidence="-1">Giles, Yvonne</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2015-03-04T14:54:09Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2015-03-04T14:54:09Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">1999</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/2086/10751</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en">Mitoxantrone is a dihydroxyanthracenedione derivative with significant clinical&#xd;
activity against advanced breast cancer, lymphoma and several types of leukaemia.&#xd;
However, as with all conventional anticancer agents, its non-specific nature results in&#xd;
dose-limiting systemic toxicity. The pharmacological (and toxicological) effects of&#xd;
mitoxantrone are thought to be mediated through its interaction with DNA and the DNA&#xd;
processing enzyme, topoisomerase II. Hence, an investigation of the DNA binding&#xd;
properties of mitoxantrone and related bis-substituted alkylaminoanthraquinones was&#xd;
undertaken with a view to developing agents with reduced toxicity to normal cells.&#xd;
DNA intercalation was evaluated using spectrophotometric and DNA thermal&#xd;
denaturation (Tm) techniques with calf thymus DNA. Overall, compounds that were&#xd;
hydroxylated at the 5 and 8 positions of the anthraquinone chromophore had increased&#xd;
DNA binding affinity compared to their non-hydroxylated analogues. The ~ Tms of&#xd;
mitoxantrone and its non-hydroxylated analogue ametantrone, were 26.4 °C and 21.5°C&#xd;
respectively. The affinity constants (K) for the chromophore-hydroxylated compounds&#xd;
were between 3.94 and 4.95 xl06M-1 while K values for their non-hydroxylated&#xd;
analogues were between 1.63 and 3.25 xl06M-l. For the di-N-oxide, AQ4N,&#xd;
intercalation was not detectable. The mono-N-oxide, AQ6N, showed modest DNA&#xd;
binding activity, with a ~Tm of7.0°C and an affinity constant of 3.64 Xl06M-l. Several&#xd;
of the alkylaminoanthraquinones were further investigated for their ability to inhibit&#xd;
decatenation of kDNA by topoisomerase II. Mitoxantrone and its analogues, AQ4 and&#xd;
AQ6, inhibited decatenation at concentrations ofO.75IlM, 1.51lM and 1.0llM&#xd;
respectively. In contrast, total inhibition of decatenation by the N-oxides, AQ4N and&#xd;
AQ6N, required concentrations of 50llM and 1 OIlM respectively. Hence modification of&#xd;
the terminal nitrogen on both alkylamino side chains to form a di-N-oxide resulted in a&#xd;
large decrease in DNA binding affinity and topoisomerase II inhibition. In view of the&#xd;
importance of the cationic alkyl amino side chains in intercalative binding and the&#xd;
enhanced ability of mitoxantrone to inhibit topoisomerase II, a series of&#xd;
acetalanthraquinones were synthesized. These compounds, referred to as YCG7 (1-&#xd;
substituted), YCG8 (l,4-bis-substituted), and YCG9 (l,5-bis-substituted), possessed&#xd;
dimethoxy groups in place of the alcohol groups of mitoxantrone, and were designed to&#xd;
be converted to their respective aldehydes, which should increase their cytotoxic activity&#xd;
due to their potential to form Schiffs bases with intracellular targets. The&#xd;
acetalanthraquinones were relatively poor DNA intercalators compared to the parent&#xd;
compound, ametantrone. The ~Tm values for YCG7, YCG8 and YCG9 were 3.6 °C,&#xd;
14.2 °C and 15.7 °C respectively. The bathochromic shifts for the acetalanthraquinones&#xd;
in the presence of calf thymus DNA and 0.5M NaCl/0.008M Tris at a DNA:drug ratio&#xd;
of 10:1 were 1.4nm, 3.5nm and 3.6nm respectively for YCG7, YCG8 and YCG9&#xd;
(ametantrone=12.2nm). Oxidative metabolism by NADPH-fortified mouse liver&#xd;
micro somes provided an effective route for the oxidation of acetalanthraquinones,&#xd;
producing two polar metabolites for YCG7 and three polar metabolites for both YCG8&#xd;
and YCG9. The metabolites ofYCG7 and YCG8 were considerably more cytotoxic&#xd;
against the V79 Chinese hamster lung cell line than their respective&#xd;
acetalanthraquinones (4.4-fold for both compounds).YCG9 was found to be relatively&#xd;
cytotoxic per se, possibly due to its different mode of DNA binding, involving&#xd;
'straddling' of the DNA helix. The increase in cytotoxicity of the metabolized products&#xd;
compared with the acetalanthraquinones supports the concept t?at they were conv.e~ed&#xd;
to their corresponding aldehydes. This leads the way to the deSIgn of acetal-contammg&#xd;
cytotoxic agents which can be selectively activated in tumours.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en">en</dim:field>
   <dim:field mdschema="dc" element="publisher" lang="en">De Montfort University</dim:field>
   <dim:field mdschema="dc" element="title" lang="en">Synthesis, DNA interactions and activation of novel cytotoxic anthraquinones.</dim:field>
   <dim:field mdschema="dc" element="type" lang="en">Thesis or dissertation</dim:field>
   <dim:field mdschema="dc" element="type" qualifier="qualificationlevel" lang="en">Doctoral</dim:field>
   <dim:field mdschema="dc" element="type" qualifier="qualificationname" lang="en">PhD</dim:field>open.access</dim:dim></metadata></record></GetRecord></OAI-PMH>